One thing I've noticed about NEU compared to other bio's is that neu don't rush the release of results.
They just make sure they have it worded correctly. And provide deep enough data that there's no doubt as to what the drug is doing.
A lot of other listed companies prefer to release marketing fluff.
NEU is a small group. They have to allocate resources. I'd be betting the massive amount of data thats needed to be submitted for the FDA Phelan McDermid meeting is priority #1
So I'll go for 3rd week of August for Anglemens. Results of FDA meeting mid September.
* I do like having a guess
Share Price, page-10970
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.18 |
Change
-0.430(3.16%) |
Mkt cap ! $1.684B | |||
| Open | High | Low | Value | Volume |
| $13.64 | $13.67 | $13.18 | $8.868M | 666.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5233 | $13.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.24 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |